This month’s Portfolio Spotlight is all about teaming up, starting with a new CEO for BlueSphere Bio, a partnership for the PHDA, and a research study from Curavi. Cavulus rounds out this month’s news, sharing their predictions on how recently eased regulations will help boost patient enrollment.
FirstWord Pharma recently featured UPMC Enterprises startup, BlueSphere Bio with that news that it has named a new CEO in veteran David Apelian. Apelian will lead the immunotherapy startup as it focuses on creating personalized therapies for cancer.
Patrick Philips, CEO of Cavulus, is predicting that Medicare Advantage plans will become more attractive than ever in the upcoming enrollment period. Phillips specifically cites recently eased rules from the Centers for Medicare & Medicaid Services as playing a big role in the shift.
Curavi Health’s study alongside Senior Helpers and Capital Coordinated Medicine was featured in McKnight’s Long-Term Care News. The study found that patients experienced as much as 44 percent cost savings and benefited from informed decisions in care escalation. The study found that “of the 33 patients in the study, only six would have been referred to an emergency room had it not been for the telepresenter service.”
The Pittsburgh Business Times was one of the first to report that Amazon Web Services, part of Amazon.com, is teaming up with the Pittsburgh Health Data Alliance (PHDA). The partnership includes a machine learning research sponsorship with “the goal of advancing innovation in areas like cancer diagnostics, precisions medicine” and more.
